Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Status Epilepticus | 3 | 2019 | 39 | 1.750 |
Why?
|
| Hippocampus | 3 | 2024 | 228 | 1.500 |
Why?
|
| Microglia | 4 | 2024 | 141 | 1.430 |
Why?
|
| Alzheimer Disease | 4 | 2024 | 324 | 1.230 |
Why?
|
| Receptor, Anaphylatoxin C5a | 3 | 2024 | 6 | 1.080 |
Why?
|
| Complement Activation | 2 | 2020 | 42 | 0.910 |
Why?
|
| Disease Models, Animal | 6 | 2024 | 1455 | 0.900 |
Why?
|
| Neurodegenerative Diseases | 2 | 2022 | 76 | 0.890 |
Why?
|
| Complement System Proteins | 1 | 2020 | 46 | 0.730 |
Why?
|
| Signal Transduction | 3 | 2024 | 1618 | 0.710 |
Why?
|
| Complement C1 Inhibitor Protein | 1 | 2019 | 3 | 0.700 |
Why?
|
| Pilocarpine | 2 | 2017 | 25 | 0.700 |
Why?
|
| Memory Disorders | 1 | 2019 | 54 | 0.670 |
Why?
|
| Complement C1q | 1 | 2017 | 9 | 0.610 |
Why?
|
| Complement C3 | 1 | 2017 | 24 | 0.610 |
Why?
|
| Body Weight | 1 | 2019 | 513 | 0.590 |
Why?
|
| CA1 Region, Hippocampal | 1 | 2016 | 24 | 0.540 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2016 | 67 | 0.530 |
Why?
|
| Epilepsy | 1 | 2017 | 174 | 0.500 |
Why?
|
| Animals | 11 | 2024 | 13187 | 0.400 |
Why?
|
| Facial Nerve | 2 | 2018 | 20 | 0.300 |
Why?
|
| Neuroglia | 1 | 2024 | 43 | 0.240 |
Why?
|
| Cell Death | 3 | 2019 | 181 | 0.230 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2017 | 1597 | 0.220 |
Why?
|
| Mice, Inbred C57BL | 3 | 2024 | 1816 | 0.210 |
Why?
|
| Mice, Transgenic | 1 | 2024 | 555 | 0.210 |
Why?
|
| Astrocytes | 1 | 2024 | 145 | 0.210 |
Why?
|
| Biological Phenomena | 1 | 2022 | 3 | 0.210 |
Why?
|
| Mice | 5 | 2024 | 5739 | 0.210 |
Why?
|
| Facial Nerve Injuries | 2 | 2018 | 3 | 0.190 |
Why?
|
| Motor Neurons | 2 | 2018 | 39 | 0.190 |
Why?
|
| Male | 5 | 2024 | 25241 | 0.180 |
Why?
|
| Gliosis | 1 | 2019 | 6 | 0.170 |
Why?
|
| Neuroprotective Agents | 1 | 2020 | 105 | 0.170 |
Why?
|
| Behavior, Animal | 1 | 2019 | 181 | 0.160 |
Why?
|
| Central Nervous System Diseases | 1 | 2018 | 27 | 0.150 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 688 | 0.150 |
Why?
|
| Miotics | 1 | 2016 | 1 | 0.140 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2016 | 10 | 0.140 |
Why?
|
| Muscarinic Agonists | 1 | 2016 | 10 | 0.140 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 164 | 0.130 |
Why?
|
| Inflammation | 1 | 2019 | 604 | 0.130 |
Why?
|
| Rats | 2 | 2019 | 3305 | 0.130 |
Why?
|
| Habituation, Psychophysiologic | 1 | 2013 | 33 | 0.120 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 973 | 0.110 |
Why?
|
| Prefrontal Cortex | 1 | 2013 | 82 | 0.110 |
Why?
|
| Interpersonal Relations | 1 | 2013 | 105 | 0.110 |
Why?
|
| Anxiety | 1 | 2013 | 274 | 0.100 |
Why?
|
| Humans | 3 | 2024 | 49974 | 0.080 |
Why?
|
| Axotomy | 2 | 2018 | 4 | 0.080 |
Why?
|
| Female | 2 | 2024 | 26472 | 0.070 |
Why?
|
| Cell Survival | 2 | 2018 | 600 | 0.070 |
Why?
|
| Long-Term Potentiation | 1 | 2024 | 31 | 0.060 |
Why?
|
| Synapses | 1 | 2024 | 87 | 0.060 |
Why?
|
| Plaque, Amyloid | 1 | 2022 | 15 | 0.050 |
Why?
|
| Disease Progression | 1 | 2022 | 825 | 0.040 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2017 | 40 | 0.040 |
Why?
|
| Superoxide Dismutase | 1 | 2017 | 113 | 0.040 |
Why?
|
| Spleen | 1 | 2017 | 172 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 427 | 0.030 |
Why?
|
| Muscimol | 1 | 2013 | 3 | 0.030 |
Why?
|
| Cycloserine | 1 | 2013 | 4 | 0.030 |
Why?
|
| GABA-A Receptor Agonists | 1 | 2013 | 2 | 0.030 |
Why?
|
| Antimetabolites | 1 | 2013 | 13 | 0.030 |
Why?
|
| Light | 1 | 2013 | 71 | 0.030 |
Why?
|
| Cues | 1 | 2013 | 49 | 0.030 |
Why?
|
| Environment | 1 | 2013 | 84 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2013 | 223 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2013 | 562 | 0.030 |
Why?
|
| Time Factors | 1 | 2013 | 2903 | 0.020 |
Why?
|